menu
    • menu

    Find Galantamine Benzoate manufacturers, exporters & distributors on PharmaCompass

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    4

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    4

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    1

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    1

    Listed Dossiers

    Listed Dossiers

    24DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    NA

    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    0

    API

    0

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    3

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Gln-1062, 224169-27-1, Galantamine benzoate, Xoi2q0zf7g, 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-, Benzgalantamine
    Molecular Formula
    C24H25NO4
    Molecular Weight
    391.5  g/mol
    InChI Key
    JKVNJTYHRABHIY-WXVUKLJWSA-N
    FDA UNII
    XOI2Q0ZF7G
    Galantamine Benzoate
    1 2D Structure

    Galantamine Benzoate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] benzoate
    2.1.2 InChI
    InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
    2.1.3 InChI Key
    JKVNJTYHRABHIY-WXVUKLJWSA-N
    2.1.4 Canonical SMILES
    CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5
    2.1.5 Isomeric SMILES
    CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5
    2.2 Other Identifiers
    2.2.1 UNII
    XOI2Q0ZF7G
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Gln-1062

    2.3.2 Depositor-Supplied Synonyms

    1. Gln-1062

    2. 224169-27-1

    3. Galantamine Benzoate

    4. Xoi2q0zf7g

    5. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Benzoate (ester), (4as,6r,8as)-

    6. Benzgalantamine

    7. Unii-xoi2q0zf7g

    8. Benzgalantamine [inn]

    9. Schembl16885442

    10. [(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] Benzoate

    11. Gln 1062

    12. Cs-6749

    13. Hy-101710

    2.4 Create Date
    2009-10-26
    3 Chemical and Physical Properties
    Molecular Weight 391.5 g/mol
    Molecular Formula C24H25NO4
    XLogP34.1
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count4
    Exact Mass391.17835828 g/mol
    Monoisotopic Mass391.17835828 g/mol
    Topological Polar Surface Area48 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity645
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    STOCK RECAP #PipelineProspector

    read-more
    read-more
    Pipeline Prospector July 2024: Indices continue to climb; Lilly buys Morphic for US$ 3.2 bn, Kisunla bags FDA nod

    Pipeline Prospector July 2024: Indices continue to climb; Lilly buys Morphic for US$ 3.2 bn, Kisunla bags FDA nod

    The biotechnology sector ended in the green for the third month in a row in July, significantly outperforming the broader market. The Nasdaq Biotechnology Index (NBI) climbed by a robust 6.6 percent, closing at 4,843.6, up from a close of 4,545.28 in June. Similarly, the SPDR S&P Biotech ETF (XBI) index surged by 6.8 percent, reaching 99.06, up from June’s closing of 92.71. The S&P Biotechnology Select Industry Index (SPSIBI) followed suit, jumping 6.8 percent to 7,716.95 compared to a 4.25 percent rise in June, when it closed at 7,225.07.The month saw a few significant deals. Eli Lilly announced the acquisition of Massachusetts-based Morphic Holding for approximately US$ 3.2 billion in cash, bolstering its presence in the US$ 26.65 billion inflammatory bowel disease (IBD) market. Lilly also signed a strategic deal with radiopharmaceutical company Radionetics Oncology for US$ 140 million, with an option to purchase the entire company for US$ 1 billion. As the month drew to a close, Boehringer Ingelheim said it is acquiring Nerio Therapeutics for up to US$ 1.3 billion, in order to expand its immuno-oncology portfolio. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel)Lilly’s donanemab finally gets approved; Dupixent okayed as add-on therapy for COPDWith the Alzheimer's Association International Conference (AAIC) taking place in Philadelphia (in the US), the spotlight was firmly on Alzheimer’s disease. In the last week of July, the US Food and Drug Administration (FDA) approved Alpha Cognition’s Zunveyl (benzgalantamine) to treat mild-to-moderate Alzheimer’s disease. In early July, and weeks prior to the conference, the FDA had granted a long-awaited approval to Eli Lilly’s donanemab, to be marketed as Kisunla, for the treatment of early symptomatic Alzheimer’s disease.In other approvals, European regulators became the first in the world to approve Sanofi and Regeneron’s Dupixent as an add-on therapy for chronic obstructive pulmonary disease (COPD) patients with high levels of certain white blood cells.In May, FDA had extended its target action date of its priority review of Dupixent as an add-on maintenance treatment for COPD by three months. The revised target action date is now September 27, 2024. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel)Merck’s RSV jab shows efficacy in infants; GSK’s Dovato measures up to Gilead’s BiktarvyMerck said its monoclonal antibody jab to protect infants against RSV-related infections has met the main goals of a mid-to-late-stage trial. Clesrovimab reduced medically attended lower respiratory infections caused by RSV through day 150. Merck plans to submit the data to global regulators. Currently, Sanofi and Astra’s Beyfortus is approved by the FDA to prevent RSV in children up to 24 months.In the largest study of its kind, GSK’s HIV drug Dovato was found to be non-inferior to Gilead Sciences’ Biktarvy, which is seen as the benchmark for HIV treatment. Significantly, Dovato did so with lesser weight gain in a 48-week head-to-head study of virologically suppressed HIV-1 patients. Both Dovato and Biktarvy are single pill treatments for HIV given once a day. Biktarvy raked in US$ 11.9 billion in 2023.Pfizer’s gene therapy for hemophilia A, giroctocogene fitelparvovec, showed promising results in a late-stage trial by significantly reducing the number of annual bleeding episodes. This brings Pfizer closer to securing FDA approval, competing with BioMarin’s Roctavian. Pfizer also said it is moving ahead to mid-stage trials with a once-daily version of its glucagon-like peptide 1 (GLP-1) drug danuglipron for weight loss. In December, Pfizer had discontinued a twice-daily version of danuglipron on account of side effects. Pfizer’s stock also benefited from its healthy second quarter (Q2) results.Swiss drugmaker Roche is reintroducing Susvimo in the US after voluntarily recalling it in October 2022. The implant used to treat patients with neovascular age-related macular degeneration (wet AMD) requires a one-time surgery to be inserted into the eye.Roche also revealed that a second drug candidate from its up to US$ 3.1 billion buyout of Carmot Therapeutics — an obesity drug —  has delivered promising results in an early-stage trial. This once-daily weight-loss pill CT-996 reduced on average 6.1 percent of participants’ starting weight after four weeks. CT-996 works in a similar manner as other blockbuster weight loss drugs, such as Wegovy and Zepbound. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel)Biogen-Sage’s essential tremor drug rejected; Novo’s weekly insulin hit with FDA’s CRL Several drugmakers faced setbacks last month. Novo Nordisk received a complete response letter (CRL) from the FDA, declining approval for its weekly insulin Awiqli. The agency requested additional information related to the manufacturing process, as well as on the type 1 diabetes indication. In May, an FDA panel had voted seven to four against the benefits of Awiqli outweighing its risks. Sage and Biogen’s partnership experienced another setback after the failure of their drug SAGE-324 in a phase 2 trial for essential tremor, a disorder that causes uncontrollable shaking of hands, arms and other parts of the body. This follows the previous failure of Zurzuvae to secure an FDA approval for clinical depression.Meanwhile, Eisai and Biogen’s Alzheimer’s drug Leqembi, faced a setback in Europe when the EU drugs regulator rejected its approval. The European Medicines Agency said the drug’s meager benefit on slowing cognitive decline in early Alzheimer’s did not outweigh the risk it brings of serious brain swelling. Leqembi is approved in the US market, where it has a new competitor — Lilly’s Kisunla.Also, BMS walked away from its rights to the ADC farletuzumab ecteribulin after having paid Japanese drugmaker Eisai US$ 650 million. As part of its portfolio reprioritization, BMS decided to end the co-development agreement. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel) Our viewAs July drew to a close, several pharma majors announced their second quarter (Q2) earnings, including Pfizer, Merck, AbbVie and, AstraZeneca. Most of these drugmakers ended up beating Wall Street expectations. For instance, Pfizer saw revenue growth in Q2 after shrinking for five quarters. It posted revenues of US$ 13.3 billion in the second quarter of 2024, compared to US$ 13 billion in the corresponding quarter last year. It has subsequently raised its 2024 guidance by US$ 1 billion. This means it’s not just the indices and share prices, but even the brass tacks — the top line and the bottomline of drugmakers — are looking up. And that may bring more cheer to the markets in August. Access the Pipeline Prospector Dashboard for July 2024 Newsmakers (Free Excel) 

    Impressions: 2546

    subscribeSubscribe

    https://www.pharmacompass.com/pipeline-prospector-blog/indices-continue-to-climb-lilly-buys-morphic-for-us-3-2-bn-its-alzheimer-s-drug-finally-bags-fda-nod

    #PharmaFlow by PHARMACOMPASS
    01 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Alpha Cognition Launches Zunveyl For Alzheimer's Disease
    Alpha Cognition Launches Zunveyl For Alzheimer's Disease

    18 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250319665873/en/Alpha-Cognition-Announces-the-Commercial-Launch-of-ZUNVEYL-Benzgalantamine-for-the-Treatment-of-Mild-to-Moderate-Alzheimers-Disease

    BUSINESSWIRE
    18 Mar 2025
    Share Share
    Alpha Cognition Secures US Patent For ZUNVEYL In Alzheimer’s
    Alpha Cognition Secures US Patent For ZUNVEYL In Alzheimer’s

    12 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250212688224/en

    BUSINESSWIRE
    12 Feb 2025
    Share Share
    Alpha Cognition Signs $44M Licensing Deal For ZUNVEYL In China
    Alpha Cognition Signs $44M Licensing Deal For ZUNVEYL In China

    08 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250108752271/en

    BUSINESSWIRE
    08 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Looking for 224169-27-1 / Galantamine Benzoate API manufacturers, exporters & distributors?

    Galantamine Benzoate manufacturers, exporters & distributors 1

    18

    PharmaCompass offers a list of Galantamine Benzoate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Galantamine Benzoate manufacturer or Galantamine Benzoate supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galantamine Benzoate manufacturer or Galantamine Benzoate supplier.

    PharmaCompass also assists you with knowing the Galantamine Benzoate API Price utilized in the formulation of products. Galantamine Benzoate API Price is not always fixed or binding as the Galantamine Benzoate Price is obtained through a variety of data sources. The Galantamine Benzoate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Galantamine Benzoate

    Synonyms

    Gln-1062, 224169-27-1, Xoi2q0zf7g, 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-, Benzgalantamine, Unii-xoi2q0zf7g

    Cas Number

    224169-27-1

    Unique Ingredient Identifier (UNII)

    XOI2Q0ZF7G

    Galantamine Benzoate Manufacturers

    A Galantamine Benzoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galantamine Benzoate, including repackagers and relabelers. The FDA regulates Galantamine Benzoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galantamine Benzoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Galantamine Benzoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Galantamine Benzoate Suppliers

    A Galantamine Benzoate supplier is an individual or a company that provides Galantamine Benzoate active pharmaceutical ingredient (API) or Galantamine Benzoate finished formulations upon request. The Galantamine Benzoate suppliers may include Galantamine Benzoate API manufacturers, exporters, distributors and traders.

    click here to find a list of Galantamine Benzoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Galantamine Benzoate GMP

    Galantamine Benzoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Galantamine Benzoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Galantamine Benzoate GMP manufacturer or Galantamine Benzoate GMP API supplier for your needs.

    Galantamine Benzoate CoA

    A Galantamine Benzoate CoA (Certificate of Analysis) is a formal document that attests to Galantamine Benzoate's compliance with Galantamine Benzoate specifications and serves as a tool for batch-level quality control.

    Galantamine Benzoate CoA mostly includes findings from lab analyses of a specific batch. For each Galantamine Benzoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Galantamine Benzoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Galantamine Benzoate EP), Galantamine Benzoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galantamine Benzoate USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search